

HSD17B14 antibody - N-terminal region

Rabbit Polyclonal Antibody

Catalog # AI14019

Product Information

Application	WB
Primary Accession	Q9BPX1
Other Accession	NM_016246 , NP_057330
Reactivity	Human, Mouse, Rat, Rabbit, Pig, Dog, Horse
Predicted	Mouse, Rat, Rabbit, Pig, Dog
Host	Rabbit
Clonality	Polyclonal
Calculated MW	28317

Additional Information

Gene ID	51171
Alias Symbol	DHRS10, retSDR3, SDR47C1
Other Names	17-beta-hydroxysteroid dehydrogenase 14, 17-beta-HSD 14, 1.1.1.-, 17-beta-hydroxysteroid dehydrogenase DHRS10, Dehydrogenase/reductase SDR family member 10, Retinal short-chain dehydrogenase/reductase retSDR3, HSD17B14, DHRS10, SDR3
Format	Liquid. Purified antibody supplied in 1x PBS buffer with 0.09% (w/v) sodium azide and 2% sucrose.
Reconstitution & Storage	Add 50 ul of distilled water. Final anti-HSD17B14 antibody concentration is 1 mg/ml in PBS buffer with 2% sucrose. For longer periods of storage, store at 20°C. Avoid repeat freeze-thaw cycles.
Precautions	HSD17B14 antibody - N-terminal region is for research use only and not for use in diagnostic or therapeutic procedures.

Protein Information

Name	HSD17B14 (HGNC:23238)
Function	Catalyzes the NAD(+)-dependent oxidation of L-fucose, yielding L-fucono-1,5-lactone, which rapidly converts spontaneously to L-fucone-1,4-lactone. Can also act on D-arabinose and L-galactose, with lower catalytic efficiency (PubMed: 38944119). Does not use NADPH (PubMed: 38944119). May be the initial enzyme of the L-fucose degradation pathway in mammals (PubMed: 17067289 , PubMed: 38944119).
Cellular Location	Cytoplasm.

Tissue Location

Highly expressed in brain, placenta, liver and kidney.


References

Haeseleer F.,et al.Methods Enzymol. 316:372-383(2000).

Clark H.F.,et al.Genome Res. 13:2265-2270(2003).

Lukacik P.,et al.Biochem. J. 402:419-427(2007).

Images



WB Suggested Anti-HSD17B14 Antibody Titration: 0.2-1
µg/ml
Positive Control: Human Small Intestine

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.